Beijing Konruns Pharmaceutical Co., Ltd. (603590.SH) announced that its self-developed KC1036 tablets (referred to as "KC1036") have successfully completed the first patient enrollment and dosing in the Phase II clinical trial titled "KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (KC1036-COM-01)." KC1036 is a Class 1 innovative chemical drug independently developed by the company, which holds global intellectual property rights for the product. KC1036 exhibits antitumor activity by inhibiting multiple targets, including VEGFR2 and AXL. The drug demonstrates strong VEGFR vascular targeting, suppressing tumor cell growth, while AXL inhibition enhances the host's antitumor immune response, thereby preventing tumor immune evasion.